WELCOME at the dexdor (dexmedetomidine) website by Orion Pharma
Critical care, including ICU-sedation and patient-centered management of pain, agitation and delirium, is one of the key expertise areas of Orion Pharma.
This website is aimed for health care professionals who can find detailed information about dexdor (dexmedetomidine). If you are not a health care professional, please consult one for further information. If you are a health care professional, please log in/register.
About dexdor (dexmedetomidine)
Dexdor (dexmedetomidine) is indicated to use for sedation of adult Intensive Care Unit patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).
Dexdor (dexmedetomidine) is contraindicated in hypersensitivity to the active substance or to any of the excipients, in advanced heart block (grade 2 or 3) unless paced, in uncontrolled hypotension, in acute cerebrovascular conditions.
Dexdor (dexmedetomidine) is for hospital use only, it should be administered by healthcare professionals skilled in the management of patients requiring intensive care.
Reference information, dexdor (dexmedetomidine)
Link to the Summary of Product Characteristics and to the Package leaflet: Information for the user, Dexdor (dexmedetomidine)
Link to the European Public Assessment Report, Dexdor (dexmedetomidine)
Dexmedetomidine in adult ICU
Effect of Sedation Regimen on Weaning from Mechanical Ventilation in the Intensive Care Unit.Nunes SL, Forsberg S, Blomqvist H, Berggren L, Sörberg M, Sarapohja T, Wickerts CJ
Clin Drug Investig
Risk Factors of Delirium in Sequential Sedation Patients in Intensive Care Units.Yang J, Zhou Y, Kang Y, Xu B, Wang P, Lv Y, Wang Z
Biomed Res Int
Effect of dexmedetomidine and midazolam for flexible fiberoptic bronchoscopy in intensive care unit patients: A retrospective study.Gao Y, Kang K, Liu H, Jia L, Tang R, Zhang X, Wang H, Yu K